Asceneuron Joins Critical Path for Alzheimer’s Disease Consortium
-
Consortium brings together industry, academic, and regulatory experts to advance research and bridge gaps in drug development targeting Alzheimer’s disease
-
Asceneuron to contribute its expertise in neurodegenerative disease to advance biomarkers for drug development in Alzheimer’s disease
Lausanne, SWITZERLAND and San Francisco, CA, USA, 26 March 2024 – Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of neurodegenerative diseases, today announces that it has joined the Critical Path Institute’s, Critical Path for Alzheimer’s Disease (CPAD) Consortium. With its highly experienced leadership team and world class Scientific Advisory Board of leading experts in neurodegenerative diseases, Asceneuron is well positioned to contribute to the consortium.
